

To: Elizabeth Holmes[eholmes@theranos.com]; Sunny Balwani[sbalwani@theranos.com]
From: Daniel Young
Sent: Mon 8/19/2013 6:12:31 AM
Importance: Normal
Subject: test launch list
Received: Mon 8/19/2013 6:12:32 AM
[Launch Summary 8 18 2013.xlsx](#)

The current launch list covers 200 tests, in both blood and urine samples. The collection of these reportables covers >97% of test frequency for these two matrices. (Note that I have not yet included TNAA tests on this list.)

Blood tests for launch include GC, ELISA and Cytometry:

- A total of 158 tests/reportables
- 48 are color chemistry
 - 3 on M1000/Tecan
 - 4 on imaging station
 - 30 on Advia with Therasnos chemistry
 - 11 on Advia with Siemens chemistry
- 92 are ELISA
 - 62 on Edison
 - 30 on Advia with Siemens chemistry
- 18 are cytometry

Urine tests for launch include GC, ELISA and Cytometry:

- A total of 47 (note that some of these are in both urine and blood)
- 25 on Iris
- 20 on Advia (with Siemens chemistry)
- 2 on Edison (ELISA)

I have attached this launch list for your review. Please let me know if you have comments before I send updates to the teams.

One major effort includes validating all 64 ELISA's on Edison devices. I am still reviewing their validation plan to see if it can be further accelerated. As I noted, including all Edison 3.0 devices (in addition to 3.5 devices) in this effort would help expedite the process. We also need to make a push to update/create all protocols based on the ELISA team's updates for moving to 3uL of sample. Having the entire ELISA team devoted to these efforts would be helpful.

Also, we have about 40 assays to verify on Advia with Siemens chemistry – this should be relatively fast since only verification is needed.

Note that urine tests on Iris and Advia do not require any validation/verification.

There are a few gaps in the top 98% for which initial launch is currently not planned, and I am following up on these with the project leaders as required. Here is my current understanding:

- automated reticulocyte count: slated for next round
- albumin, urine: may need to include Theranos chemistry
- Ketones (beta-hydroxybutyrate): TBD
- troponin, quant (tCNI): launching with troponin T instead
- acid (d-lysergic acid diethylamide, LSD, LSD-25, lysergide): under development
- butorphanol (Stadol, Stadolol): TBD
- flunitrazepam (Rohypnol, Rohipnol): TBD
- Codeine (opiate screen): TBD
- Ipecac :TBD
- Nalbuphine, Nubain: TBD
- lyme disease antibody: this is a confirmatory test, traditionally western blot
- inf a / inf b: this CPT requires visual observation
- fibrin degradation, quant: under development

Thanks,

Daniel Young, PhD

Vice President, Theranos Systems

Theranos, Inc

1601 S. California Ave

Palo Alto, CA 94304

650-470-6119 (office)

650-804-8185 (mobile)

PRIVILEGED AND CONFIDENTIAL COMMUNICATION

IMPORTANT – This electronic transmission, and any files transmitted with it are confidential and/or legally privileged information. This information is intended solely for the use of the individual or entity to which it is addressed. Any disclosure, retransmission, reproduction, dissemination or other use of the contents of this information by persons or entities other than the intended recipient is strictly prohibited. If you have received this email in error, please contact us immediately and delete all copies. Please note that any views or opinions presented in this email are solely those of the author and do not necessarily represent those of Theranos, Inc. Finally, before opening or using attachments the recipient should check this email and any attachments for the presence of viruses. Theranos, Inc. accepts no liability for any damage caused by any virus transmitted by this email. Our sole responsibility is limited to resupplying any affected attachments.

Theranos, Inc., 3200 Hillview Avenue, Palo Alto, CA, 94304

650-838-9292 www.theranos.com

File Produced in Native Format